Ensemble Therapeutics

Ensemble Therapeutics Corporation is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2004 by Harvard chemist David R. Liu, the company develops and is attempting to bring to market synthetic macrocycle drugs, that is, compounds with a characteristic macrocyclic ring structure, under the trademark Ensemblins. If successful, Ensemblins would be a new class of drugs between small molecules and biologics. An orally ACTIVE antagonist to Interleukin 17 has been demonstrated in animal models.

Management

Michael D. Taylor became president and chief executive officer in 2007. Nick K. Terrett has been the chief scientific officer since 2006. Founder David R. Liu chairs the scientific advisory board.

Ownership

Ensemble is principally owned by Flagship Ventures, a venture capital firm whose founder, Noubar Afeyan, chairs its board. Other investors include ARCH Venture Partners, CMEA, Harris & Harris, Kisco Ltd., and Boston University. As of 2012, Ensemble has raised $38.5 million of equity financing.

Partnerships

Ensemble has entered into partnerships that allow its macrocycle libraries to be accessed for the purpose of affinity screening [...] discovery against targets that are otherwise difficult to address. Partner firms include Boehringer Ingelheim, Genentech, Bristol-Myers Squibb, and Pfizer.